Bris­tol My­ers Squibb fi­nal­ly gets in the front­line NSCLC game dom­i­nat­ed by Mer­ck, adding a sec­ond Op­di­vo/Yer­voy-based ...

6 years ago
Pharma
FDA+

In lat­est can­cer deal, Bris­tol My­ers Squib­b's new BD chief bets $65M in search for more tar­gets like PARP

6 years ago
Deals

Ab­Cellera rais­es $105M in first ma­jor ven­ture round as Covid-19 an­ti­body nears clin­ic

6 years ago
Financing

Ex-biotech chief pleads guilty in col­lege ad­mis­sions scan­dal, faces a 10-month prison stretch in plea deal

6 years ago
People

Biotech Voic­es: Coro­n­avirus will change biotech re­search with re­mote col­lab­o­ra­tions

6 years ago
Biotech Voices
Coronavirus

Daphne Koller’s AI start­up gets $143M in new cash from a16z, oth­ers

6 years ago
Financing
Startups

Takeda's Alun­brig wins lung can­cer ap­proval; Atara of­fers an­oth­er pos­i­tive MS drug up­date

6 years ago
News Briefing

PhII Alzheimer's da­ta loom­ing, Sh­iono­gi spend­ing up to $500M on a buy­out in­volv­ing one of the tough­est bets in ...

6 years ago
Deals

Be­yond cold stor­age: Tech­nol­o­gy de­signed to keep or­gans warm, helps liv­er trans­plant pa­tients in key study

6 years ago
R&D

Al­ny­lam nabs speedy re­view, set­ting up 3rd pos­si­ble ap­proval in 3 years

6 years ago
R&D
FDA+

As biotech IPOs siz­zle on vir­tu­al Wall Street, 3 new play­ers roll the dice on meg­a­money gam­bles top­ping $325M

6 years ago
Financing

Ex-Ax­o­vant crew at Arvelle ups Se­ries A haul, de­ploy­ing $200M-plus to com­mer­cial­ize epilep­sy drug in Eu­rope

6 years ago
Financing

Af­ter years of part­ner­ships, AI biotech Ex­sci­en­tia lands first ma­jor fi­nanc­ing round at $60M

6 years ago
Financing
AI

Backed by BAR­DA, Mer­ck jumps in­to Covid-19: buy­ing out a vac­cine, part­ner­ing on an­oth­er and adding an­tivi­ral to the ...

6 years ago
R&D
Coronavirus

Piv­otal myas­the­nia gravis da­ta from ar­genx au­gur well for FcRn in­hibitors in de­vel­op­ment

6 years ago
R&D

Covid-19 roundup: Jun­shi, Eli Lil­ly ready to launch Covid-19 an­ti­body tri­al; Janet Wood­cock steps aside — for now ...

6 years ago
Coronavirus

Af­ter de­cou­pling from Re­gen­eron, Sanofi says it’s time to sell the $13B stake picked up in the mar­riage

6 years ago
Deals
R&D

Re­searchers de­fine ex­act­ly what they saw in the first pos­i­tive remde­sivir study for Covid-19. But what's that worth ...

6 years ago
Bioregnum
Coronavirus

Re­struc­tured Melin­ta now wants to buy fel­low an­tibi­ot­ic mak­er Tetraphase; TA As­so­ciates mulls $500M deal for a stake ...

6 years ago
News Briefing

An­oth­er NASH de­lay for In­ter­cept frus­trates in­vestors, shares wilt

6 years ago
R&D

Ger­man Mer­ck bests US Mer­ck in UK copy­right tus­sle of Mer­ck v. Mer­ck

6 years ago
Pharma

The man who led Gilead’s au­toim­mune piv­ot heads to Boston; No­var­tis gets a new chief for its AI In­no­va­tion Cen­ter

6 years ago
Peer Review

FDA ap­proves the first gener­ic for Amar­in's Vas­cepa — but is a fish oil price war im­mi­nent?

6 years ago
Pharma
FDA+

GSK inks $231M man­u­fac­tur­ing deal as Hal Bar­ron an­tic­i­pates fruit­ful year for pruned R&D group

6 years ago
Outsourcing
First page Previous page 839840841842843844845 Next page Last page
A service from the Financial Times